This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Generic-Drug Stocks Still Under the Weather

Laegeler says Par is in the midst of a risky strategy of expanding its development of brand-name drugs. These products have higher profit margins than do generics, but they're more expensive to make and market.

With a market cap of $634 million, Par is making a decision that is creating uncertainty in the minds of investors and analysts. Thomson Reuters reports five analysts are neutral and one has a sell rating.

Teva, Barr and Watson make some brand-name drugs; Mylan tried to do so, but it has decided to focus on generics. Sell-side analysts support Teva, and they still like Barr and Mylan. Thomson Reuters says each company has more buy ratings than the combined neutral and sell ratings. Watson has few buy ratings, with most analysts neutral.

Morningstar assigns its top, 5-star rating for Barr, Mylan and Watson. Based on their fundamentals, they are trading so far below their fair values that Laegeler says they're worth buying. Teva earns four stars, and Par gets two.

Forecasting a Comback

For investors with short-term outlooks, Barr has been the biggest disappointment. Its stock plunged from $49.65 on May 7 to $38.10 the next day after Barr issued first-quarter results that fell below expectations and lowered its full-year earnings forecast.

Barr blamed weaker U.S. generic results, higher R&D expenses and under-performance by Plan B, the emergency contraception pill. Barr promised the second half of 2008 would be better.

Merrill Lynch and Goldman Sachs cut their ratings to neutral from buy, and Zacks Investment Research dropped its rating to sell from hold. However, S.G. Cowen raised its rating to outperform from market perform.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
WPI $85.73 0.00%
MYL $72.80 1.50%
NVS $103.50 -0.39%
TEVA $60.57 -1.70%
AAPL $134.13 1.10%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs